{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:22:18Z","timestamp":1791858138689,"version":"4.3.4"},"reference-count":134,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["NEIP30EY01730"],"award-info":[{"award-number":["NEIP30EY01730"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000305","name":"Sight Research UK","doi-asserted-by":"publisher","award":["SAC054"],"award-info":[{"award-number":["SAC054"]}],"id":[{"id":"10.13039\/501100000305","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["224586\/Z\/21\/Z"],"award-info":[{"award-number":["224586\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222064\/Z\/20\/Z"],"award-info":[{"award-number":["222064\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X502856\/1"],"award-info":[{"award-number":["MR\/X502856\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012617","name":"Moorfields Eye Hospital NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012617","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001285","name":"UCL Institute of Ophthalmology, University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012618","name":"NIHR Moorfields Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ymthe.2026.02.018","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:09:57Z","timestamp":1773421797000},"page":"2840-2862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Microglia-independent rAAV-induced inflammation causes persistent ocular immune dysregulation rescued by S1P receptor modulation"],"prefix":"10.1016","volume":"34","author":[{"given":"Philip M.","family":"Langer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Clare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suci","family":"Cendanawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie L.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver H.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Kai","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn L.","family":"Pepple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4044-4952","authenticated-orcid":false,"given":"David A.","family":"Copland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.02.018_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Sig Transduct Target Ther."},{"key":"10.1016\/j.ymthe.2026.02.018_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.02.018_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2026.02.018_bib4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","article-title":"Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper","volume":"26","author":"Yang","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.02.018_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.02.018_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/tvst.10.4.3","article-title":"Inflammation in Viral Vector-Mediated Ocular Gene Therapy: A Review and Report From a Workshop Hosted by the Foundation Fighting Blindness, 9\/2020","volume":"10","author":"Chan","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2025.101354","article-title":"Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy","volume":"106","author":"Purdy","year":"2025","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ymthe.2026.02.018_bib8","first-page":"5312","article-title":"Meta-analysis of Gene Therapy Associated Uveitis (GTAU)","volume":"65","author":"Buckley","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2026.02.018_bib9","doi-asserted-by":"crossref","first-page":"1001263","DOI":"10.3389\/fimmu.2022.1001263","article-title":"rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib10","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.oret.2022.06.013","article-title":"Intravitreal Delivery of rAAV2tYF-CB-hRS1 Vector for Gene Augmentation Therapy in Patients with X-Linked Retinoschisis: 1-Year Clinical Results","volume":"6","author":"Pennesi","year":"2022","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.ymthe.2026.02.018_bib11","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I\/IIa Trial by Intravitreal Delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.018_bib12","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.02.018_bib13","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41433-022-02262-5","article-title":"Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy","volume":"37","author":"Jalil","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ymthe.2026.02.018_bib14","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber's congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.02.018_bib15","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","article-title":"A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders","volume":"32","author":"Vrellaku","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.018_bib16","doi-asserted-by":"crossref","first-page":"10654","DOI":"10.1182\/blood-2022-159017","article-title":"The Effects of Immunomodulation with Corticosteroids to Manage an AAV Capsid Immune response in the Phase I\/II Study of SPK-8011","volume":"140","author":"Evans","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.02.018_bib17","article-title":"The clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysis","volume":"28","author":"Liu","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2026.02.018_bib18","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2026.02.018_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.eye.6701895","article-title":"Corticosteroid-induced glaucoma: a review of the literature","volume":"20","author":"Kersey","year":"2006","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ymthe.2026.02.018_bib20","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ymthe.2025.01.028","article-title":"Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age","volume":"33","author":"Clare","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.018_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1167\/iovs.62.2.41","article-title":"Characterization of Gene Therapy Associated Uveitis Following Intravitreal Adeno-Associated Virus Injection in Mice","volume":"62","author":"Tummala","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2026.02.018_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.omtm.2021.05.011","article-title":"Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina","volume":"22","author":"Chandler","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.02.018_bib23","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","article-title":"AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye","volume":"25","author":"Reichel","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.018_bib24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41586-024-07130-8","article-title":"Compartmentalized ocular lymphatic system mediates eye-brain immunity","volume":"628","author":"Yin","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.02.018_bib25","doi-asserted-by":"crossref","first-page":"9989","DOI":"10.1073\/pnas.1820387116","article-title":"Retinal microglia initiate neuroinflammation in ocular autoimmunity","volume":"116","author":"Okunuki","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.02.018_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103417","article-title":"Preventing the antigen-presenting function of retinal microglia blocks autoimmune neuroinflammation by dendritic cell-primed CD4(+) T cells","volume":"153","author":"Shirahama","year":"2025","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ymthe.2026.02.018_bib27","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41586-023-05788-0","article-title":"Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy","volume":"615","author":"Chen","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.02.018_bib28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1172\/JCI97229","article-title":"Microglia are required for protection against lethal coronavirus encephalitis in mice","volume":"128","author":"Wheeler","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.02.018_bib29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.immuni.2019.02.007","article-title":"Microglial Function Is Distinct in Different Anatomical Locations during Retinal Homeostasis and Degeneration","volume":"50","author":"O\u2019Koren","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.02.018_bib30","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.4049\/jimmunol.173.6.3916","article-title":"Microglia Initiate Central Nervous System Innate and Adaptive Immune Responses through Multiple TLRs","volume":"173","author":"Olson","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib31","doi-asserted-by":"crossref","first-page":"7377","DOI":"10.1167\/iovs.15-17587","article-title":"Retinal Microglial Activation Following Topical Application of Intracellular Toll-Like Receptor Ligands","volume":"56","author":"Chinnery","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2026.02.018_bib32","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/s41590-022-01360-6","article-title":"Cognate microglia-T cell interactions shape the functional regulatory T cell pool in experimental autoimmune encephalomyelitis pathology","volume":"23","author":"Haimon","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrn3710","article-title":"Microglial phagocytosis of live neurons","volume":"15","author":"Brown","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ymthe.2026.02.018_bib34","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","article-title":"The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases","volume":"47","author":"Krasemann","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.02.018_bib35","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1177\/11206721211049001","article-title":"The change of microglia numbers within the mice retina, optic nerve and chiasm following intravitreal AAV2-GFP injection","volume":"32","author":"Ji","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib36","article-title":"Single Eye mRNA-Seq Reveals Normalisation of the Retinal Microglial Transcriptome Following Acute Inflammation","volume":"10","author":"Bell","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib37","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.immuni.2021.09.014","article-title":"Microglia: Immune and non-immune functions","volume":"54","author":"Borst","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.02.018_bib38","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1126\/science.aax6752","article-title":"Microglia monitor and protect neuronal function through specialized somatic purinergic junctions","volume":"367","author":"Cser\u00e9p","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.02.018_bib39","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/JVI.02272-12","article-title":"Stimulation of NF-\u03baB Activity by the HIV Restriction Factor BST2","volume":"87","author":"Tokarev","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: From adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib41","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1476-9255-7-31","article-title":"The role of Qa-2, the functional homolog of HLA-G, in a Behcet's disease-like mouse model induced by the herpes virus simplex","volume":"7","author":"Lee","year":"2010","journal-title":"J. Inflamm."},{"key":"10.1016\/j.ymthe.2026.02.018_bib43","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.3389\/fimmu.2018.02894","article-title":"New Insights Into the Role of Qa-2 and HLA-G Non-classical MHC-I Complexes in Malignancy","volume":"9","author":"da Silva","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib44","doi-asserted-by":"crossref","first-page":"E3160","DOI":"10.1073\/pnas.1212753109","article-title":"C1q limits dendritic cell differentiation and activation by engaging LAIR-1","volume":"109","author":"Son","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.02.018_bib45","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41577-025-01181-2","article-title":"Inhibitory pattern recognition receptors: lessons from LAIR1","volume":"25","author":"Pascoal Ramos","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-020-0371-y","article-title":"Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases","volume":"16","author":"Hardy","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-022-00784-6","article-title":"Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases","volume":"18","author":"Burg","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib48","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin inhibitors: 40 years later, can't live without","volume":"191","author":"Azzi","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1084\/jem.20061839","article-title":"Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity","volume":"204","author":"Dunn","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.02.018_bib52","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.4049\/jimmunol.178.7.4129","article-title":"Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms","volume":"178","author":"Wohlfert","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib53","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41584-023-01002-7","article-title":"TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond","volume":"19","author":"Siegmund","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.02.018_bib55","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.02.018_bib56","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/archopht.126.10.1390","article-title":"Fingolimod (FTY720) as an Acute Rescue Therapy for Intraocular Inflammatory Disease","volume":"126","author":"Raveney","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib57","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ajpath.2011.10.008","article-title":"Therapeutic Dosing of Fingolimod (FTY720) Prevents Cell Infiltration, Rapidly Suppresses Ocular Inflammation, and Maintains the Blood-Ocular Barrier","volume":"180","author":"Copland","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.preteyeres.2018.03.001","article-title":"Re-programming immunosurveillance in persistent non-infectious ocular inflammation","volume":"65","author":"Epps","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ymthe.2026.02.018_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/biom14010122","article-title":"Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study","volume":"14","author":"Fischer","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2026.02.018_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100516","article-title":"Dose-Dependent Progression of Chorioretinal Atrophy at the Injection Site After Subretinal Injection of rAAV2\/8 in Nonhuman Primates","volume":"4","author":"Seitz","year":"2024","journal-title":"Ophthalmol. Sci."},{"key":"10.1016\/j.ymthe.2026.02.018_bib61","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00251-016-0932-z","article-title":"The role of MHC class Ib-restricted T cells during infection","volume":"68","author":"Anderson","year":"2016","journal-title":"Immunogenetics"},{"key":"10.1016\/j.ymthe.2026.02.018_bib62","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/bjo.79.9.834","article-title":"Flow cytometric identification of a minority population of MHC class II positive cells in the normal rat retina distinct from CD45lowCD11b\/c+CD4low parenchymal microglia","volume":"79","author":"Dick","year":"1995","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib63","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00424-017-1947-5","article-title":"Macrophage physiology in the eye","volume":"469","author":"Chinnery","year":"2017","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.ymthe.2026.02.018_bib64","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12974-017-0915-5","article-title":"MHC class II expression and potential antigen-presenting cells in the retina during experimental autoimmune uveitis","volume":"14","author":"Lipski","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ymthe.2026.02.018_bib65","article-title":"Retinal Muller Glia Initiate Innate Response to Infectious Stimuli via Toll-Like Receptor Signaling","volume":"7","author":"Kumar","year":"2012","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ymthe.2026.02.018_bib66","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.exer.2015.06.012","article-title":"Expression of Toll-like receptors in human retinal and choroidal vascular endothelial cells","volume":"138","author":"Stewart","year":"2015","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ymthe.2026.02.018_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors \u2013 Implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ymthe.2026.02.018_bib68","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamaophthalmol.2018.6902","article-title":"Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1\/2 Clinical Trial","volume":"137","author":"Bouquet","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib69","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajo.2022.11.026","article-title":"Safety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic Neuropathy","volume":"249","author":"Vignal-Clermont","year":"2023","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib70","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.ymthe.2021.02.013","article-title":"Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I\/IIa gene therapy trial","volume":"29","author":"Mishra","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.018_bib71","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1167\/iovs.63.3.30","article-title":"Antimetabolite Drugs Exhibit Distinctive Immunomodulatory Mechanisms and Effects on the Intestinal Microbiota in Experimental Autoimmune Uveitis","volume":"63","author":"Lloren\u00e7","year":"2022","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2026.02.018_bib72","first-page":"1760","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ymthe.2026.02.018_bib73","doi-asserted-by":"crossref","first-page":"eabq4419","DOI":"10.1126\/scitranslmed.abq4419","article-title":"Additive efficacy of a bispecific anti\u2013TNF\/IL-6 nanobody compound in translational models of rheumatoid arthritis","volume":"15","author":"Biesemann","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.02.018_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25126732","article-title":"IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis","volume":"25","author":"Dema","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.02.018_bib75","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-018-1164-y","article-title":"Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation","volume":"15","author":"Valentin-Torres","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ymthe.2026.02.018_bib76","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-016-0513-y","article-title":"Sustained TNF production by central nervous system infiltrating macrophages promotes progressive autoimmune encephalomyelitis","volume":"13","author":"Valentin-Torres","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ymthe.2026.02.018_bib77","doi-asserted-by":"crossref","first-page":"20878","DOI":"10.1073\/pnas.0709205105","article-title":"Therapeutic B cell depletion impairs adaptive and autoreactive CD4+T cell activation in mice","volume":"104","author":"Bouaziz","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.02.018_bib78","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib79","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","article-title":"Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects","volume":"81","author":"Chun","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2026.02.018_bib80","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010818-021358","article-title":"Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders","volume":"59","author":"Chun","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib81","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.ymthe.2026.02.018_bib82","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.02.018_bib83","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ophtha.2012.12.040","article-title":"Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis","volume":"120","author":"Zarbin","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2026.02.018_bib84","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12348-020-00215-1","article-title":"Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis","volume":"10","author":"Sonne","year":"2020","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"10.1016\/j.ymthe.2026.02.018_bib85","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1212\/WNL.0000000000001462","article-title":"Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2026.02.018_bib86","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2026.02.018_bib87","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.02.018_bib88","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/bph.13641","article-title":"Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk","volume":"174","author":"Sugahara","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib89","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/ctm.ctm_7_17","article-title":"SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models","volume":"3","author":"Hengst","year":"2017","journal-title":"Cancer Transl. Med."},{"key":"10.1016\/j.ymthe.2026.02.018_bib90","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.1021\/acs.jmedchem.1c02171","article-title":"Discovery of In Vivo Active Sphingosine-1-phosphate Transporter (Spns2) Inhibitors","volume":"65","author":"Fritzemeier","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ymthe.2026.02.018_bib91","doi-asserted-by":"crossref","first-page":"eabj2681","DOI":"10.1126\/scitranslmed.abj2681","article-title":"Sphingosine 1-phosphate signaling in perivascular cells enhances inflammation and fibrosis in the kidney","volume":"14","author":"Tanaka","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.02.018_bib92","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.cell.2023.04.028","article-title":"Structural and functional insights into Spns2-mediated transport of sphingosine-1-phosphate","volume":"186","author":"Chen","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.02.018_bib93","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41589-021-00930-3","article-title":"Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism","volume":"18","author":"Xu","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib94","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1124\/mol.108.049783","article-title":"Full Pharmacological Efficacy of a Novel S1P1 Agonist That Does Not Require S1P-Like Headgroup Interactions","volume":"74","author":"Gonzalez-Cabrera","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib95","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.intimp.2011.07.004","article-title":"The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice","volume":"11","author":"Tarras\u00f3n","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-49893-8","article-title":"Pseudoirreversible inhibition elicits persistent efficacy of a sphingosine 1-phosphate receptor 1 antagonist","volume":"15","author":"Maruyama","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.02.018_bib97","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coph.2015.05.017","article-title":"PI3K inhibitors in inflammation, autoimmunity and cancer","volume":"23","author":"Stark","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib98","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.02.018_bib99","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.02.018_bib100","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/08923973.2022.2055565","article-title":"LY294002 attenuates inflammatory response in endotoxin-induced uveitis by downregulating JAK3 and inactivating the PI3K\/Akt signaling","volume":"44","author":"Wu","year":"2022","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib101","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-\u03b4 and PI3K-\u03b3 Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867015","article-title":"A Comprehensive Atlas of Immunological Differences Between Humans, Mice, and Non-Human Primates","volume":"13","author":"Bjornson-Hooper","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101309","article-title":"Characterization of AAV vectors: A review of analytical techniques and critical quality attributes","volume":"32","author":"Kontogiannis","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.02.018_bib104","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41596-021-00644-9","article-title":"IBEX: an iterative immunolabeling and chemical bleaching method for high-content imaging of diverse tissues","volume":"17","author":"Radtke","year":"2022","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2026.02.018_bib105","doi-asserted-by":"crossref","first-page":"33455","DOI":"10.1073\/pnas.2018488117","article-title":"IBEX: A versatile multiplex optical imaging approach for deep phenotyping and spatial analysis of cells in complex tissues","volume":"117","author":"Radtke","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.02.018_bib106","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1167\/iovs.12-9662","article-title":"The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL\/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes","volume":"53","author":"Mattapallil","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2026.02.018_bib107","series-title":"InterEdgeDistance Version 2.0","author":"Patnaik","year":"2023"},{"key":"10.1016\/j.ymthe.2026.02.018_bib108","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2026.02.018_bib109","first-page":"473","article-title":"Multimodal analysis of ocular inflammation using the endotoxin-induced uveitis mouse model","volume":"9","author":"Chu","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ymthe.2026.02.018_bib110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2004.04.015","article-title":"Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice","volume":"153","author":"Webb","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib111","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000479185","article-title":"Behavioral Conditioning of Immune Responses with Cyclosporine A in a Murine Model of Experimental Autoimmune Uveitis","volume":"24","author":"Bauer","year":"2017","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.ymthe.2026.02.018_bib112","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0306-3623(97)00331-5","article-title":"Cyclosporin A and FK-506 inhibit development of superantigen-potentiated collagen-induced arthritis in mice","volume":"30","author":"Takaoka","year":"1998","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib113","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4049\/jimmunol.179.2.1369","article-title":"B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity","volume":"179","author":"Yanaba","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib114","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.4049\/jimmunol.1402608","article-title":"Cutting edge: NF-kappaB p65 and c-Rel control epidermal development and immune homeostasis in the skin","volume":"194","author":"Grinberg-Bleyer","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib115","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1111\/ajt.12823","article-title":"Donor CD4 T cells trigger costimulation blockade-resistant donor bone marrow rejection through bystander activation requiring IL-6","volume":"14","author":"Hock","year":"2014","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2026.02.018_bib116","series-title":"FastQC: A Quality Control Tool for High Throughput Sequence Data V. 0.12.0","year":"2010"},{"key":"10.1016\/j.ymthe.2026.02.018_bib117","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.02.018_bib118","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2026.02.018_bib119","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.02.018_bib120","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.02.018_bib121","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btv566","article-title":"Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data","volume":"32","author":"Okonechnikov","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.02.018_bib122","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","article-title":"MultiQC: summarize analysis results for multiple tools and samples in a single report","volume":"32","author":"Ewels","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.02.018_bib123","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007664","article-title":"Tximeta: Reference sequence checksums for provenance identification in RNA-seq","volume":"16","author":"Love","year":"2020","journal-title":"Plos Comput. Biol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib125","article-title":"ComBat-seq: batch effect adjustment for RNA-seq count data","volume":"2","author":"Zhang","year":"2020","journal-title":"NAR Genom. Bioinform."},{"key":"10.1016\/j.ymthe.2026.02.018_bib126","doi-asserted-by":"crossref","first-page":"W415","DOI":"10.1093\/nar\/gkae456","article-title":"faster gene set analysis and new support for metabolomics and multi-omics","volume":"52","author":"Elizarraras","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.02.018_bib127","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","article-title":"ShinyGO: a graphical gene-set enrichment tool for animals and plants","volume":"36","author":"Ge","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.02.018_bib128","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1258\/acb.2009.009077","article-title":"A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies","volume":"46","author":"Ito","year":"2009","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.ymthe.2026.02.018_bib129","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/hum.2020.281","article-title":"Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes","volume":"32","author":"Chung","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.02.018_bib130","series-title":"The 34th Annual ACM Symposium on User Interface Software and Technology","first-page":"754","author":"Elkin","year":"2021"},{"key":"10.1016\/j.ymthe.2026.02.018_bib131","first-page":"143","article-title":"The aligned rank transform for nonparametric factorial analyses using only anova procedures","volume":"35","author":"Wobbrock","year":"2011","journal-title":"Proc. SIGCHI Conf. Hum. Factor Comput. Syst."},{"key":"10.1016\/j.ymthe.2026.02.018_bib132","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jclinepi.2014.03.012","article-title":"False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies","volume":"67","author":"Glickman","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ymthe.2026.02.018_bib133","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/biomet\/93.3.491","article-title":"Adaptive linear step-up procedures that control the false discovery rate","volume":"93","author":"Benjamini","year":"2006","journal-title":"Biometrika"},{"key":"10.1016\/j.ymthe.2026.02.018_bib134","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B: Stat. Methodol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626001048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626001048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:34:06Z","timestamp":1781829246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626001048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":134,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1525001626001048"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.02.018","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microglia-independent rAAV-induced inflammation causes persistent ocular immune dysregulation rescued by S1P receptor modulation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}